海思科医药集团股份有限公司第五届董事会第二十八次会议决议公告

Group 1 - The company held its 28th meeting of the fifth board of directors on May 30, 2025, via communication voting, with all five directors participating [1][2] - The board approved the appointment of Mr. Yan Pangkai as the general manager, effective from the date of the board's approval [2][47] - The board also approved the change of the legal representative to Mr. Yan Pangkai due to business development needs [4][5] Group 2 - The board approved the appointment of Mr. Wang Ruibin as the deputy general manager, effective from the date of the board's approval [6][7] - The board approved the supplementary election of Mr. Yan Pangkai as a non-independent director candidate, pending approval from the shareholders' meeting [9][11] - The board approved the revision of the company's articles of association, which requires special resolution approval from the shareholders' meeting [11][55] Group 3 - The company received a notice of acceptance for the IND application of the innovative drug HSK47388, which is intended for the treatment of autoimmune diseases [51][52] - HSK47388 is a self-developed oral drug that has shown potential in preclinical studies for its ability to inhibit inflammation and good tolerability [52]